PROCEDURES FOR THE TREATMENT OF AUTOIMMUNITY DISEASES IN A SUBJECT AND IN VITRO DIAGNOSTIC TESTS.

摘要

Use of (a) at least one interferon antagonist that reduces the activity of a type I interferon, and (b) at least one antagonist of the Flt3 ligand (Flt3L) that reduces the activity of a Flt3L, for the preparation of a medicament. containing the at least one interferon antagonist and the at least one Flt3 ligand antagonist (Flt3L) in an amount effective for the treatment of systemic lupus erythematosus (SLE) in a subject in need, where the at least one Interferon antagonist is selected from the group consisting of anti-IFN-α monoclonal antibodies and their antigen-binding fragments, and wherein the at least one Flt3 ligand antagonist is selected from the group consisting of anti-Flt3L monoclonal antibodies and antigen binding fragments.